Because the evolving nature of clinical drug development for nonalcoholic fatty liver disease (NAFLD) and steatohepatitis (NASH), there are many researchers working towards a better understanding of the disease and solutions to improve clinical trial design and methods. But, to date, there are few opportunities for key scientists in this indication to share experience and knowledge and collaborate to improve existing approaches.
The NASH Roundtable™ was established in 2018 as a platform to stimulate collaboration and dialogue and to build consensus towards validated biomarkers and endpoints and to support the development of effective and safe treatments.  Today the Roundtable consists of distinguished physicians, researchers and clinical development experts from three continents brought together by their common commitment to steward advances in science, clinical research and therapeutics for NAFLD and NASH.

Key Pillars of the NASH Roundtable™ Initiative

Comprised of leading scientific and clinical development experts in NASH

Advancing science, methods, clinical planning, study design, and protocol development for NASH

Accessible to biopharma to consult on NASH development programs

For Information About the NASH Roundtable™ Contact Us